Vision-Sciences Inc. (NASDAQ:CGNT) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating. Vision-Sciences’ rating score has improved by 66.7% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 1-year consensus target price of $2.20 for the company and are anticipating that the company will post ($0.04) EPS for the current quarter, according to Zacks. Zacks has also given Vision-Sciences an industry rank of 161 out of 265 based on the ratings given to its competitors.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Vision-Sciences from a “hold” rating to a “sell” rating in a report on Friday, August 5th. Roth Capital raised shares of Vision-Sciences from a “neutral” rating to a “buy” rating in a report on Wednesday, September 7th.

An institutional investor recently raised its position in Vision-Sciences stock. Renaissance Technologies LLC increased its stake in shares of Vision-Sciences Inc. (NASDAQ:CGNT) by 4.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 319,163 shares of the medical device company’s stock after buying an additional 12,600 shares during the period. Renaissance Technologies LLC owned 1.22% of Vision-Sciences worth $351,000 as of its most recent SEC filing. 30.43% of the stock is owned by institutional investors and hedge funds.

Shares of Vision-Sciences (NASDAQ:CGNT) opened at 1.6101 on Thursday. The stock’s 50 day moving average is $1.57 and its 200 day moving average is $1.16. The stock’s market capitalization is $42.09 million. Vision-Sciences has a 12 month low of $0.71 and a 12 month high of $1.99.

Vision-Sciences (NASDAQ:CGNT) last issued its earnings results on Tuesday, August 2nd. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by $0.11. Vision-Sciences had a negative return on equity of 27.43% and a negative net margin of 13.99%. Analysts anticipate that Vision-Sciences will post ($0.21) earnings per share for the current fiscal year.

Vision-Sciences Company Profile

Cogentix Medical, Inc, formerly Vision-Sciences, Inc, is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU).

5 Day Chart for NASDAQ:CGNT

Get a free copy of the Zacks research report on Vision-Sciences (CGNT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vision-Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision-Sciences Inc. and related companies with's FREE daily email newsletter.